张小涛, 张 真①, 韩淑红①, 马学真, 王 静②. 不能手术的非小细胞肺癌同步放化疗对血清CD44v6 和VEGF表达水平的影响及其临床意义*[J]. 中国肿瘤临床, 2010, 37(5): 260-263. DOI: 10.3969/j.issn.1000-8179.2010.05.006
引用本文: 张小涛, 张 真①, 韩淑红①, 马学真, 王 静②. 不能手术的非小细胞肺癌同步放化疗对血清CD44v6 和VEGF表达水平的影响及其临床意义*[J]. 中国肿瘤临床, 2010, 37(5): 260-263. DOI: 10.3969/j.issn.1000-8179.2010.05.006
shu
ZHANG Xiaotao1, ZHANG Zhen2, HAN Shuhong2, MA Xuezhen1, WANG Jing3. Effect of Concurrent Chemoradiotherapy on Patients'Serum CD 44v6 and VEGF Levels and Its Clinical Significance[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2010, 37(5): 260-263. DOI: 10.3969/j.issn.1000-8179.2010.05.006
Citation: ZHANG Xiaotao1, ZHANG Zhen2, HAN Shuhong2, MA Xuezhen1, WANG Jing3. Effect of Concurrent Chemoradiotherapy on Patients'Serum CD 44v6 and VEGF Levels and Its Clinical Significance[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2010, 37(5): 260-263. DOI: 10.3969/j.issn.1000-8179.2010.05.006
shu

不能手术的非小细胞肺癌同步放化疗对血清CD44v6 和VEGF表达水平的影响及其临床意义*

Effect of Concurrent Chemoradiotherapy on Patients'Serum CD 44v6 and VEGF Levels and Its Clinical Significance

    摘要
  • 摘要: 目的：检测不能手术的非小细胞肺癌（NSCLC ）患者同步放化疗前、后血清CD44v6 和VEGF（sCD 44v6，sVEGF ）表达水平，探讨其动态变化规律与不能手术NSCLC 病理生理特征、疗效及预后的相关性。方法：采用生物素- 亲和素系统ELISA 双抗体夹心法定量检测50例不能手术NSCLC 患者同步放化疗前、后血清CD44v6 和VEGF的表达水平。结果：1）治疗前CD44v6 水平（570.89± 63.30）ng/L 和VEGF水平（241.09± 85.96）ng/L 均显著高于对照组（356.32± 97.68）ng/L（P<0.01）与（103.72± 39.22）ng/L（P<0.05）。 2）治疗前VEGF表达水平与原发肿瘤大小、远处转移、细胞分化及临床分期等有显著相关性（P<0.05），与原发部位、淋巴结转移和组织学类型等无明显相关性（P>0.05）。 而CD44v6 表达水平与原发肿瘤大小、远处转移、细胞分化、临床分期、淋巴结转移及组织学类型等有显著相关性（P<0.05），与原发部位、性别和年龄无明显相关性（P>0.05）。 3）治疗前CD44v6 水平（570.89±63.30）ng/L 和VEGF 水平（241.09± 85.96）ng/L 均分别高于治疗后的水平（281.44± 74.28）ng/L（P<0.01）和（133.64± 67.69）ng/L（P<0.01）。 4）治疗后CD44v6 和VEGF平均水平与治疗前比较，CR组显著降低（P<0.01），PD组降低不明显（P>0.05），而PR组和SD组降低介于两者之间（P<0.05）。 5）治疗前、后CD44v6 和VEGF 水平呈正相关（r=0.291，P<0.05）。 结论：同步放化疗前后CD44v6/VEGF水平与不能手术NSCLC 的多项临床病理特征密切相关。它们的水平变化是预测不能手术NSCLC 生物学行为的有用指标，可为临床判断疗效及预后提供依据。

     

    Abstract: Objective: To investigate the changes in serum CD44v6/v EGF (sCD 44v6/sVEGF) levels after concurrent chemoradiotherapy in patients with inoperable non-small cell lung cancer (NSCLC) patients and to analyze the correlation of serum markers with patients' prognosis. Methods:The sCD 44v6/v EGF levels were detected by ELISA in 50inoperable NSCLC patients before and after concurrent chemoradiotherapy. Results: The sCD 44v6 and sVEGF levels before treatment was significantly higher than that in the control group. The pre-treatment sVEGF level was closely related to cTNM stage, metastasis, cell differentiation and primary tumor size, but was not correlated with histological classification, lymph node status, age or gender. The pre-treatment sCD44v6 level was closely correlated with cTNM stage, metastasis, cell differenti -ation, and primary tumor size, but was not correlated with histological classification, age or gender. Patients’sCD 44v6 be-fore treatment ( 570 .89± 63.30ng/L) was significantly higher than that after treatment (281 .44± 74.28ng/L). Patients’s VEGF before treatment (241 .09± 85.96ng/L) was significantly higher than that after treatment (133 .64± 67.69ng/L). PD patients had the highest level of sCD 44v6 and sVEGF and CR patients had the lowest sCD 44v6 and sVEGF level. The sVEGF lev -el was highly correlated with sCD 44v6 (r=0.291 , P<0.05). Conclusion:The sCD 44v6 and sVEGF levels might be helpful for evaluation of the biological behavior and prognosis of NSCLC.

     

    • HTML全文
    • 参考文献(0)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回